Navigation Links
The Good, Bad, Ugly of Midwest Biotech in 2003

The Good

Lets start with the good in Midwest biotech in 2003. Whats clearly striking is the outstanding performance of the publicly traded Midwest biotech companies as measured by the ePrairie Midwest Biotech Index, which evaluates the top 20 biotech stocks of the region.

Last week, I commented on the stellar performance of the Nasdaq and Amex Biotech indices, which grew ......

Full article >>> almost $19 billion raised by the biotech community in the U.S. during 2003 (an excellent year), Midwest companies accounted for a small amount of this sum (some $300 million to $400 million, both private and public) or about 2 percent of total money raised.

Considering that at least 20 percent of biotech and life science companies are located in the eight-state Midwest region, this is a......

Full article >>> ol.com. This article has been syndicated on the Wisconsin Technology Network courtesy of ePrairie, a user-driven business and technology news community distributed via the Web, the wireless Web and free daily e-mail newsletters. They can be found at www.eprairie.com.

*****
The opinions expressed herein or statements made in the ......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 01/06/04


Related biology technology :

1. Growth: the Good, the Bad, and the Ugly
2. Midwest life science stocks kept sizzling in Q2
3. Midwest life science stocks sizzle in a tepid first quarter
4. A Midwest passage to India, Part II
5. Midwest offers non-stop flight to North Carolina research park
6. A Midwest life-science odyssey comes full circle
7. Midwest hotter for healthcare investments
8. A Midwest small-cap, life-science surprise package
9. 2006: A mixed blessing for Midwest life science companies
10. Midwest gaining stature in nanotech research
11. Midwest colleges strong contenders for NIH funds
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/17/2017)... February 17, 2017 According ... by Product (Consumables, Service), Type (Safety, Efficacy, Validation), ... Drug Discovery and Development, Disease-Risk) - Global Forecast ... projected to reach USD 53.34 Billion by 2021 ... a CAGR of 13.8% during the forecast period ...
(Date:2/17/2017)... Calif. , Feb. 17, 2017  Protagonist ... detailing data on its oral peptide drug candidates, ... Congress of the European Crohn,s and Colitis Organization ... Barcelona, Spain from February ... posters detail preclinical data on Protagonist drug candidates ...
(Date:2/16/2017)... Calif. and GREENWICH, Conn. ... a private investment firm focused on venture growth ... the promotion of Josh Richardson , M.D. ... on investments in biotechnology companies.  He is a ... played important roles in Longitude,s investments in Aimmune ...
Breaking Biology Technology:
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Biology News(10 mins):